Meet the faculty
Program Director
Tina Vilsbøll
Tina Vilsbøll (MD DMSc) is a consultant endocrinologist, Professor of Endocrinology and Research Leader at Steno Diabetes Center Copenhagen (SDCC), University of Copenhagen, Denmark. Prof. Vilsbøll has been involved in diabetes and metabolic research since 1995 and her research focusses on human metabolism, regulation of appetite and food intake and the pathophysiology of obesity and related disorders including prediabetes and several different types of diabetes. Vilsbøll and her team have reported several novel findings describing the integrative role of the gut and the liver in human (patho-)physiology. Prof. Vilsbøll has authored 409 peer-reviewed scientific publications and she has received several honours for her research. She is currently the Honorary Secretary and board member for the European Association for the Study of Diabetes (EASD), she serves as a referee for several international journals including The Lancet and British Medical Journal and is a member of numerous professional societies and committees.
Disclosures
Tina Vilsbøll has served on scientific advisory panels, been part of speaker’s bureaus, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Mundipharma, MSD/Merck, Novo Nordisk, Sanofi and Sun Pharmaceuticals.
Nikolaus Marx
Nikolaus Marx, is Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I, University Hospital Aachen, Germany. He received his medical training at the Universities of Mainz, Genf (Switzerland) and Düsseldorf, obtaining his MD in 1994. His thesis on growth regulation in human renal cancer cell lines was completed at the laboratory of Professor Gerharz at the Institute of Pathology, University of Mainz. After a post-doctoral fellowship with Dr. Peter Libby and Dr. Jorge Plutzky at Brigham and Women’s Hospital, Harvard Medical School, Nikolaus Marx later became a board-certified internist, then cardiologist, before specialising in intensive care medicine in internal medicine at the University of Ulm. He was appointed Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I at the University of Aachen in 2009.
Disclosures
Nikolaus Marx has served on scientific advisory panels, been part of speaker’s bureaus, served as a consultant to and/or received research support from Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, Lilly, NovoNordisk
Advisory board: Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, NovoNordisk
Nikolaus Marx declines all personal compensation from pharma or device companies
David Cherney
Following his clinical training in Nephrology, Dr. Cherney completed his PhD in human renal physiology at the Institute of Medical Science, University of Toronto in 2008. He is currently Professor in the Department of Medicine, University of Toronto and a Clinician Scientist at the University Health Network and Mount Sinai Hospitals, where he is director of the Renal Physiology Laboratory. He is supported by the Canadian Institutes of Health Research, the JDRF, the Heart and Stroke Richard Lewar Centre of Excellence, the Heart and Stroke Foundation of Canada and the Banting and Best Diabetes Centre. He is also supported by a Department of Medicine, University of Toronto Merit Award. Dr. Cherney’s research program focuses on physiological factors that initiate renal disease in patients with diabetes, such as renal hyperfiltration and inflammation, and the role of the cardiorenal axis in diabetes. His research group is also involved in early and late phase clinical trials in the cardiorenal-metabolic field, including several primary renal outcome trials in patients with and without diabetes. Dr. Cherney’s research program is closely aligned with his integrated and multidisciplinary cardiac-renal-endocrine clinic at the University Health Network, which maintains a strong emphasis on the prevention of diabetic nephropathy and cardiovascular disease. In 2019, he received the American Society of Nephrology (ASN) Distinguished Researcher Award for outstanding contributions to nephrology. In 2019 he also received the Diabetes Canada/CIHR – Institute of Nutrition Diabetes and Metabolism (INMD) Young Scientist Award.
Disclosures
David Cherney has served on scientific advisory panels, been part of speaker’s bureaus, served as a consultant to and/or received research support from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago, GSK and Novo-Nordisk and has operational
Pinar Topsever
Dr. F. Pınar Topsever is Professor of Family Medicine and chairing the department of Family Medicine at Acıbadem Mehmet Ali Aydınlar University School of Medicine in Istanbul, Turkey, where she is involved in undergraduate, as well as, postgraduate teaching and training. She is involved in several national and international academic CME-CPD activities (especially about primary care management of PWD) for PCPs. Dr. Topsever is PCDE (Primary Care Diabetes Europe) Vice-Chair. She acted as scientific Secretary and/or local organizer of major PC conferences (PCDE, WONCA Europe, EGPRN) and is editorial board member of peer-reviewed scientific journals and referee in a number of scientific funding – award committees.
Her fields of interest are care for PWD in primary care, epidemiology in the context of health promotion and preventive care, evidence-based-medicine and research methodology. Dr. Topsever regularly presents the results of her research at scientific conferences and publishes them in peer-reviewed journals.
Disclosures
Pinar Topsever has served on scientific advisory panels, been part of speaker’s bureaus, served as a consultant to and/or received research support from: Eli Lilly, Merck, AstraZeneca, Lifescan. Also participated in a company sponsored speaker bureau with Astra Zeneca.
In 2021–2023 PCDE as a society, has received corporate sponsorship from AstraZeneca, Eli Lilly, Novo Nordisk, and Roche Diagnostics, but the companies had no input in the study protocols.
